American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases
Therapeutic drug monitoring (TDM), which involves measurement of drug or active
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …
Tailoring anti-TNF therapy in IBD: drug levels and disease activity
S Ben-Horin, Y Chowers - Nature reviews Gastroenterology & …, 2014 - nature.com
The treatment of IBD with anti-TNF agents has substantially evolved since their first
introduction more than a decade ago. The robust efficacy witnessed in many patients has …
introduction more than a decade ago. The robust efficacy witnessed in many patients has …
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab
H Yanai, L Lichtenstein, A Assa, Y Mazor… - Clinical …, 2015 - Elsevier
Background & Aims There is controversy about whether levels of anti–tumor necrosis factor
(TNF) and antidrug antibodies (ADAs) are accurate determinants of loss of response to …
(TNF) and antidrug antibodies (ADAs) are accurate determinants of loss of response to …
[HTML][HTML] Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis
OJ Adedokun, WJ Sandborn, BG Feagan, P Rutgeerts… - Gastroenterology, 2014 - Elsevier
Background & Aims We analyzed data collected during the Active Ulcerative Colitis Trials
(ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and …
(ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and …
Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease
Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based …
SK Murthy, J Begum, EI Benchimol, CN Bernstein… - Gut, 2020 - gut.bmj.com
Objectives To better understand the real-world impact of biologic therapy in persons with
Crohn's disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace …
Crohn's disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace …
Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study
I Dotan, Y Ron, H Yanai, S Becker… - Inflammatory bowel …, 2014 - academic.oup.com
Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …
it may be associated with side effects and loss of response. One loss of response …
Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis
SE Berends, AS Strik, M Löwenberg… - Clinical …, 2019 - Springer
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology, probably
caused by a combination of genetic and environmental factors. The treatment of patients …
caused by a combination of genetic and environmental factors. The treatment of patients …
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
T Van Stappen, NV Casteele, G Van Assche… - Gut, 2018 - gut.bmj.com
Objective To evaluate the clinical relevance of antidrug antibodies (ADAs) measured using a
drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted …
drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted …
Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease
C Moore, G Corbett, AC Moss - Journal of Crohn's and Colitis, 2016 - academic.oup.com
Background and Aims: A number of observational studies have reported an association
between serum levels of infliximab [IFX] at various thresholds, and clinical outcomes in …
between serum levels of infliximab [IFX] at various thresholds, and clinical outcomes in …